Efficacy and Safety of Low Dose Naltrexone for Chronic Pain

References

• Duramed Pharmaceuticals. Revia drug insert. New York: Medical Sciences; 2013.
   Google Scholar
• Toljan K, Vrooman B. Low-Dose Naltrexone (LDN)—review of therapeutic utilization. Med Sci. 2018;6(4):82.
   Google Scholar
• Bruun-Plesner K, Blichfeldt-Eckhardt MR, Vaegter HB, Lauridsen JT, Amris K, Toft P. Low-dose naltrexone for the treatment of fibromyalgia: investigation of dose–response relationships. Pain Med. 2020;21(10):2253–61. doi:10.1093/pm/pnaa001.
   PubMed Web of Science ®Google Scholar
• Raknes G, Småbrekke L. A sudden and unprecedented increase in low dose naltrexone (LDN) prescribing in Norway. Patient and prescriber characteristics, and dispense patterns. A drug utilization cohort study. Pharmacoepidemiol Drug Saf. 2017;26(2):136–42. doi:10.1002/pds.4110.
   PubMed Web of Science ®Google Scholar
• Bihari B, Drury FM, Ragone VP, Ottomanelli GA, Buimovici-Klein E, Orbe MG, Foeste WF, Thomas JR, Kirk, RP Low dose naltrexone in the treatment of acquired immune deficiency syndrome. Poster presentation at the IV international AIDS conference, Stockholm, Sweden; 1988.
   Google Scholar
• Bihari B, Strub SO. Efficacy of low dose naltrexone as an immune stabilizing agent for the treatment of HIV/AIDS. AIDS Patient Care. 1995;9(1):3. doi:10.1089/apc.1995.9.3.
   PubMedGoogle Scholar
• Qu N, Meng Y, Handley MK, Wang C, Shan F. Preclinical and clinical studies into the bioactivity of low-dose naltrexone (LDN) for oncotherapy. Int Immunopharmacol. 2021;96:107714. doi:10.1016/j.intimp.2021.107714.
   PubMed Web of Science ®Google Scholar
• Ekelem C, Juhasz M, Khera P, Mesinkovska NA. Utility of naltrexone treatment for chronic inflammatory dermatologic conditions: a systematic review. JAMA Dermatol. 2019;155(2):229–36. doi:10.1001/jamadermatol.2018.4093.
   PubMed Web of Science ®Google Scholar
• Parker CE, Nguyen TM, Segal D, Macdonald JK, Chande N. Low dose naltrexone for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2018;4(4):CD010410. doi:10.1002/14651858.CD010410.pub3.
   PubMedGoogle Scholar
• Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10(4):663–72. doi:10.1111/j.1526-4637.2009.00613.x.
   PubMed Web of Science ®Google Scholar
• Kim PS, Fishman MA. Low-dose naltrexone for chronic pain: update and systemic review. Curr Pain Headache Rep. 2020;24(10):64. doi:10.1007/s11916-020-00898-0.
   PubMed Web of Science ®Google Scholar
• Jiang BC, Liu T, Gao YJ. Chemokines in chronic pain: cellular and molecular mechanisms and therapeutic potential. Pharmacol Ther. 2020;212:107581. doi:10.1016/j.pharmthera.2020.107581.
   PubMed Web of Science ®Google Scholar
• Younger J, Noor N, McCue R, MacKey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529–38. doi:10.1002/art.37734.
   PubMed Web of Science ®Google Scholar
• Parkitny L, Younger J. Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for Fibromyalgia. Biomedicines. 2017;5(2):16. doi:10.3390/biomedicines5020016.
   PubMed Web of Science ®Google Scholar
• Turel AP, Oh KH, Zagon IS, McLaughlin PJ. Low dose naltrexone for treatment of multiple sclerosis: a retrospective chart review of safety and tolerability. J Clin Psychopharmacol. 2015;35(5):609–11. doi:10.1097/JCP.0000000000000373.
   PubMed Web of Science ®Google Scholar
• Bronfenbrener R. Inexpensive compounding of low-dose naltrexone (LDN) with orange juice. J Am Acad Dermatol. 2021;85(3):e139. doi:10.1016/j.jaad.2019.03.067.
   PubMed Web of Science ®Google Scholar
• Fawcett JP, Morgan NC, Woods DJ. Formulation and stability of naltrexone oral liquid for rapid withdrawal from methadone. Ann Pharmacother. 1997;31(11):1291–5. doi:10.1177/106002809703101102.
   PubMed Web of Science ®Google Scholar
• Good Rx Naltrexone, generic revia. [Internet]. Good Rx. [cited 2023 Sep 9]. Available from: https://www.goodrx.com/naltrexone?ppid=85083&form=tablet&dosage=50mg&quantity=2&label_override=naltrexone.
   Google Scholar
• Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain. 2012;13(8):715–24. doi:10.1016/j.jpain.2012.03.009.
   PubMed Web of Science ®Google Scholar
• Martin SJ, McAnally HB, Okediji P, Rogosnitzky M. Low-dose naltrexone, an opioid-receptor antagonist, is a broad-spectrum analgesic: a retrospective cohort study. Pain Manag. 2022;12(6):699–709. doi:10.2217/pmt-2021-0122.
   PubMed Web of Science ®Google Scholar
• Krebs EE, Lorenz KA, Bair MJ, Damush TM, Wu J, Sutherland JM, Asch SM, Kroenke K. Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference. J Gen Intern Med. 2009;24(6):733–8. doi:10.1007/s11606-009-0981-1.
   PubMed Web of Science ®Google Scholar
• Norman G. Likert scales, levels of measurement and the “laws” of statistics. Adv Health Sci Educ Theory Pract. 2010;15(5):625–32. doi:10.1007/s10459-010-9222-y.
   PubMed Web of Science ®Google Scholar
• Ostelo RWJG, Deyo RA, Stratford P, Waddell G, Croft P, Von Korff M, Bouter LM, de Vet HC. Interpreting change scores for pain and functional status in low back pain: towards international consensus regarding minimal important change. Spine (Phila Pa 1976). 2008;33(1):90–4. doi:10.1097/BRS.0b013e31815e3a10.
   PubMed Web of Science ®Google Scholar
• Frahm Olsen M, Bjerre E, Hansen MD, Tendal B, Hilden J, Hróbjartsson A. Minimum clinically important differences in chronic pain vary considerably by baseline pain and methodological factors: systematic review of empirical studies. J Clin Epidemiol. 2018;101:87–106.e2. doi:10.1016/j.jclinepi.2018.05.007.
   PubMed Web of Science ®Google Scholar
• Olsen MF, Bjerre E, Hansen MD, Hilden J, Landler NE, Tendal B, Hróbjartsson A. Pain relief that matters to patients: systematic review of empirical studies assessing the minimum clinically important difference in acute pain. BMC Med. 2017;15(1):35. doi:10.1186/s12916-016-0775-3.
   PubMed Web of Science ®Google Scholar
• Srinivasan A, Dutta P, Bansal D, Chakrabarti A, Bhansali AK, Hota D. Efficacy and safety of low-dose naltrexone in painful diabetic neuropathy: a randomized, double-blind, active-control, crossover clinical trial. J Diabetes. 2021;13(10):770–8. doi:10.1111/1753-0407.13202.
   PubMed Web of Science ®Google Scholar
• Ioannidis JPA. Why most discovered true associations are inflated. Epidemiology. 2008;19(5):640–8. doi:10.1097/EDE.0b013e31818131e7.
   PubMed Web of Science ®Google Scholar